Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal furosemide and fluticasone for obstructive sleep apnea
IRCT20240526061903N2Phase 3Completed
- Sponsor
- Vice Chancellor for Research, Birjand University of Medical Sciences
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of furosemide and fluticasone in obstructive sleep apnea hypopnea syndrome (OSAHS) (8 arms), sponsored by Vice Chancellor for Research, Birjand University of Medical Sciences. Primary endpoints: Pittsburgh Sleep Quality Index, oxygen saturation and 1 more. Started Aug 2024; status: completed.
02
Drugs
furosemidefluticasone
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on IRCT20240526061903N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240526061903N2.